Skip to main content
. 2019 Dec 13;20(24):6302. doi: 10.3390/ijms20246302

Figure 2.

Figure 2

Effects of etanercept-secretome on the expression of proteins in the livers of mice with liver fibrosis. (A) Effects of etanercept-secretome on the expression of inflammation-related proteins (TNF-α and CD68) in LX2 HSCs. In the LX2 HSCs with TAA treatment, the expression levels of TNF-α and CD68 were significantly lower in etanercept-secretome group than in control group. (B) Effects of etanercept-secretome on the expression of fibrosis-related (MMP2, p-SMAD, TGF-β, and α-SMA) in LX2 HSCs. In the LX2 HSCs with TAA treatment, the expression levels of these fibrosis-related proteins were significantly lower in etanercept-secretome group than in control group. (C) Western blot analysis of the livers obtained from the mice with liver fibrosis following individual treatments (control secretome and etanercept-secretome). Expression levels of inflammation- (TNF-α, CD68, and F4/80) and fibrosis-related proteins (TGF-β, COL1A1, MMP2, and TIMP-1) in the liver specimens were investigated following individual treatments. Relative densities of individual markers had been quantified using Image J software and then were normalized to that of β-actin in each group. The values are presented as mean ± standard deviation of three independent experiments. Abbreviations: α-SMA, alpha smooth muscle actin; COL1A1, collagen type 1 alpha1; CS, secretome obtained from empty vector-transfected ASCs; Ct, control; ES, etanercept-secretome (the secretome obtained from etanercept-synthesizing ASCs); HSC, hepatic stellate cell; MMP2, metalloproteinases-2; Sal, saline injection group; TNF-α, tumor necrosis factor-α; TIMP-1, tissue inhibitor of metalloproteinases-1; TGF-β, transforming growth factor-β; TNF-α, tumor necrosis factor-α.